Medicinal Chemicals & Botanical Products · SIC 2833

NATURAL ALTERNATIVES INTERNATIONAL INC

NAII

Watch

Latest revenue

$35.5M

as of 2026-03-31

Latest net income

$-4.3M

as of 2026-03-31

Net margin

-12.1%

as of 2026-03-31

Price · 5Y

-28.7% / yr 42.5 pts / yr vs S&P 500 81.5% total
Compare:

Live market

delayed ≤15 min
$2.55
0.78%
Market cap
$16.0M
Enterprise value
$16.0M
P/E (trailing)
Forward P/E
P/B
Dividend yield
0.0%
52-wk high
$4.96
52-wk low
$2.33
Beta
Shares out
6.3M

5-year trend

What this company does

AI

ITEM 1. BUSINESS General Our vision is to enrich the world through the best of nutrition. We are a leading formulator, manufacturer and marketer of nutritional supplements. Our comprehensive strategic partnerships with our customers allow us to offer a wide range of innovative nutritional products and services to such customers including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review, and international product registration assistance. As our primary business activity, we provide private-label contract…

AI summary unavailable — showing raw filing excerpt

Generated from NAII's filing dated 2025-09-23

Key risks

AI

ITEM 1A. RISK FACTORS When evaluating our business and future prospects, you should carefully review and consider the risks described below in conjunction with other information in this report and in other reports and documents we file with the SEC. The risks and uncertainties described below are not the only ones we face. Additional material risks and uncertainties, not presently known to us, or that we currently see as immaterial, may also occur or become material. If any of the following risks or any additional risks and uncertainties actually occur or become material, our business, financial condition and results of operations could be seriously harmed. In that event, the market price…

AI summary unavailable — showing raw filing excerpt

Generated from NAII's filing dated 2025-09-23

Profitability

Gross margin

7.2%

18.6%

Operating margin

-6.7%

11.1%

Net margin

-10.5%

64.8%

Return on equity

-19.8%

127.0%

Return on assets

-8.9%

101.0%

Leverage

Debt / equity

1.22×

26.4%

Long-term debt / equity

0.13×

16.6%

Debt / assets

55.0%

11.9%

Earnings tracker

QuarterRevenueYoYNet incomeYoYNet margin

Q1 2026

2026-03-31

$35.5M+23.3%$-4.3M-97.2%-12.1%

Q4 2025

2025-12-31

$34.8M+2.1%$-2.6M-16.5%-7.3%

Q3 2025

2025-09-30

$37.7M+13.8%$-291.0K+85.3%-0.8%

Q2 2025

2025-06-30

$33.9M+14.8%$-7.2M-285.1%-21.3%

Q1 2025

2025-03-31

$28.8M+14.4%$-2.2M-38.5%-7.6%

Q4 2024

2024-12-31

$34.1M+35.2%$-2.2M+28.6%-6.4%

Q3 2024

2024-09-30

$33.1M-2.4%$-2.0M-185.2%-6.0%

Q2 2024

2024-06-30

$29.5M$-1.9M-6.4%

Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.

Industry trend

Medicinal Chemicals & Botanical Products · SIC 2833

No data yet for industry average

Your notes

Keep private notes on NAII — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to write a note

Insider activity

Insider buying

$26.8K

Insider selling

$0

Net activity

+$26.8K

Distinct insiders

1

Open-market trades over the last 365 days.

Recent transactions

DateInsiderTypeSharesPriceValue
2026-03-06

Mark A Ledoux

CEO/Chairman

Purchase532$2.80$1.5K
2026-03-05

Mark A Ledoux

CEO/Chairman

Purchase218$2.75$600
2026-03-04

Mark A Ledoux

CEO/Chairman

Purchase500$2.77$1.4K
2026-03-02

Mark A Ledoux

CEO/Chairman

Purchase500$2.79$1.4K
2026-02-27

Mark A Ledoux

CEO/Chairman

Purchase500$2.85$1.4K
2026-02-27

Mark A Ledoux

CEO/Chairman

Purchase250$2.80$700
2026-02-26

Mark A Ledoux

CEO/Chairman

Purchase500$2.85$1.4K
2026-02-25

Mark A Ledoux

CEO/Chairman

Purchase500$2.81$1.4K
2026-02-24

Mark A Ledoux

CEO/Chairman

Purchase1,000$2.71$2.7K
2026-02-23

Mark A Ledoux

CEO/Chairman

Purchase750$2.70$2.0K
2026-02-20

Mark A Ledoux

CEO/Chairman

Purchase250$2.65$664
2026-02-19

Mark A Ledoux

CEO/Chairman

Purchase1,500$2.56$3.8K
2026-02-18

Mark A Ledoux

CEO/Chairman

Purchase500$2.56$1.3K
2026-02-17

Mark A Ledoux

CEO/Chairman

Purchase2,500$2.60$6.5K

Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.

Who owns NAII

Institutional value

$3.7M

Total shares held

1.4M

Distinct holders

10

-13 vs prior

As of

2026-03-31

Prior: 2025-12-31

Filers with $100M+ AUM disclose holdings 45 days after quarter end.

Top institutional holders

#ManagerSharesValueQoQ changeAction
1CALDWELL SUTTER CAPITAL, INC.498.8K$1.3M+37.0K (+8.0%)Added
2DIMENSIONAL FUND ADVISORS LP354.7K$933.0K-29.8K (-7.7%)Trimmed
3Mink Brook Asset Management LLC293.7K$772.5K+0 (+0.0%)No change
4VANGUARD CAPITAL MANAGEMENT LLC210.9K$554.6KNew
5VANGUARD FIDUCIARY TRUST CO27.1K$71.3KNew
6JAMES INVESTMENT RESEARCH, INC.10.0K$26.4K+0 (+0.0%)No change
7Vanguard Global Advisers, LLC2.8K$7.4KNew
8CITIGROUP INC2.0K$5.2K+2.0K (+199000.0%)Added
9GILL CAPITAL PARTNERS, LLC7$18New
10SBI Securities Co., Ltd.5$13+0 (+0.0%)No change

Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.

Top questions investors are asking

Coming once NAII's latest filing finishes processing.